We recently published a list of Billionaire Ken Griffin’s 10 Midcap Stock Picks with Huge Upside Potential. In this article, ...

We recently published a list of 15 Small-Cap Healthcare Stocks Hedge Funds Are Buying. In this article, we are going to take ...

We recently published a list of Here’s What Fueled These 10 Firms’ Surge. In this article, we are going to take a look at ...

Neurocrine Biosciences, the American biotech, has unveiled new data showing its drug Crenessity (crinecerfont) may help ...

Q1 2025 Earnings Call Transcript May 5, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS is $0 ...

Neurocrine stock gains as Q1 EPS beats estimates; Ingrezza sales climb 8% YoY with record new patients and strong analyst ...

Ratings for Neurocrine Biosciences NBIX +0.37% Get Free Report were provided by 19 analysts in the past three months, ...

In both children and adults, the drug allows for decreasing glucocorticoid dosing to physiological levels while still ...

In patients with classic congenital adrenal hyperplasia, crinecerfont conferred meaningful reductions in glucocorticoid dose ...

Neurocrine on Tuesday unveiled a new campaign in which the “Hold On” singer will encourage people with tardive dyskinesia (TD ...

Good day, everyone, and welcome to Neurocrine Biosciences Reports First Quarter 2025 Results. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask ...

Todd Tushla; Investor Relations; Neurocrine Biosciences Inc. Kyle Gano; Chief Business Development and Strategy Officer; Neurocrine Biosciences Inc. Matthew Aberneth ...